Tempest TherapeuticsTPST
NASDAQPharmaceuticals
No cached AI snapshot yet for TPST.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
4 employees14.34M shares outstandinglisted 2021-06-28
Next earnings ~May 5, 2026
About Tempest Therapeutics
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Latest News
Showing market-wide stock news
Tempest Therapeutics stock surges on Senlang CAR-T deal
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Related Stocksin Pharmaceuticals
Ready to see the live AI view on TPST?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing TPST side-by-side with live signals.